Abstract
The investment firm Ampersand Capital has acquired Louisville, Kentucky–based Peptides International and merged it with New England Peptide, one of its portfolio companies. Peptides International will add catalog and custom synthesis services to New England Peptide’s custom design and manufacturing services for pharmaceutical peptide and antibody products. “This transaction adds meaningful scale, capabilities, customer relationships, and a similarly strong market reputation to what we have built,” says Sam Massoni, CEO of New England Peptide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
